M402, a novel Heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Zhou, He ^a   Roy, Sucharita ^a   Cochran, Edward ^a   Zouaoui, Radouane ^a   Chu, Chia Lin ^a   Duffner, Jay ^a   Zhao, Ganlin ^a   Smith, Sean ^a   Galcheva Gargova, Zoya ^a   Karlgren, Juliane ^a   Dussault, Nancy ^a   Kwan, Rain Y Q ^a   Moy, Erick ^a   Barnes, Marishka ^a   Long, Alison ^a   Honan, Chris ^a   Qi, Yi Wei ^a   Shriver, Zachary ^a   Ganguly, Tanmoy ^a   Schultes, Birgit ^a   Venkataraman, Ganesh ^a   Kishimoto, Takashi Kei ^a   more..

^a Momenta Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DALTEPARIN; DOCETAXEL; HEPARAN SULFATE; M 402; M ONC 202; UNCLASSIFIED DRUG; DRUG DERIVATIVE; M402 HEPARAN SULFATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BREAST CARCINOMA; CELL MOTILITY; COLON CARCINOMA; CONTROLLED STUDY; DEPOLYMERIZATION; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SAFETY; FEMALE; IC 50; MALE; MELANOMA; MICROVASCULATURE; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SUPPRESSOR CELL; TUMOR GROWTH; ANIMAL; DISEASE COURSE; EXPERIMENTAL MELANOMA; FLOW CYTOMETRY; METASTASIS; MOLECULAR MIMICRY; PATHOLOGY; SURFACE PLASMON RESONANCE; TUMOR CELL LINE; VASCULARIZATION;

ANIMALIA; MURINAE; MUS;

ANIMALS; CELL LINE, TUMOR; DISEASE PROGRESSION; FLOW CYTOMETRY; HEPARITIN SULFATE; MELANOMA, EXPERIMENTAL; MICE; MOLECULAR MIMICRY; NEOPLASM METASTASIS; SURFACE PLASMON RESONANCE;

EID: 79959266354     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021106     Document Type: Article

References (46)

1. Wels J, Kaplan RN, Rafii S, Lyden D, (2008) Migratory neighbors and distant invaders: tumor-associated niche cells. Genes Dev 22: 559-574.
2. Shojaei F, Wu X, Malik AK, Zhong C, Baldwin ME, et al. (2007) Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol 25: 911-920.
3. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, et al. (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15: 220-231.
4. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, et al. (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15: 232-239.
5. Mayer RJ, (2009) Targeted therapy for advanced colorectal cancer-more is not always better. N Engl J Med 360: 623-625.
6. Psaila B, Lyden D, (2009) The metastatic niche: adapting the foreign soil. Nat Rev Cancer 9: 285-293.
7. Sasisekharan R, Venkataraman G, (2000) Heparin and heparan sulfate: biosynthesis, structure and function. Curr Opin Chem Biol 4: 626-631.
8. Senger DR, Perruzzi CA, Feder J, Dvorak HF, (1986) A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 46: 5629-5632.
9. Folkman J, Klagsbrun M, Sasse J, Wadzinski M, Ingber D, et al. (1988) A heparin-binding angiogenic protein-basic fibroblast growth factor-is stored within basement membrane. Am J Pathol 130: 393-400.
10. Hoogewerf AJ, Kuschert GS, Proudfoot AE, Borlat F, Clark-Lewis I, et al. (1997) Glycosaminoglycans mediate cell surface oligomerization of chemokines. Biochemistry 36: 13570-13578.
11. Hamon M, Mbemba E, Charnaux N, Slimani H, Brule S, et al. (2004) A syndecan-4/CXCR4 complex expressed on human primary lymphocytes and macrophages and HeLa cell line binds the CXC chemokine stromal cell-derived factor-1 (SDF-1). Glycobiology 14: 311-323.
12. Yang L, Huang J, Ren X, Gorska AE, Chytil A, et al. (2008) Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 13: 23-35.
13. Goon PK, Lip GY, Boos CJ, Stonelake PS, Blann AD, (2006) Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer. Neoplasia 8: 79-88.
14. Ostrand-Rosenberg S, Sinha P, (2009) Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 182: 4499-4506.
15. Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, et al. (2001) Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci U S A 98: 3352-3357.
16. Esko JD, Rostand KS, Weinke JL, (1988) Tumor formation dependent on proteoglycan biosynthesis. Science 241: 1092-1096.
17. Kim JB, Urban K, Cochran E, Lee S, Ang A, et al. (2010) Non-invasive detection of a small number of bioluminescent cancer cells in vivo. PLoS One 5: e9364.
18. Nagasawa K, Inoue Y, Kamata T, (1977) Solvolytic desulfation of glycosaminoglycuronan sulfates with dimethyl sulfoxide containing water or methanol. Carbohydr Res 58: 47-55.
19. Korff T, Augustin HG, (1999) Tensional forces in fibrillar extracellular matrices control directional capillary sprouting. J Cell Sci 112 (Pt 19): 3249-3258.
20. Watson SA, Morris TM, Crosbee DM, Hardcastle JD, (1993) A hepatic invasive human colorectal xenograft model. Eur J Cancer 29A: 1740-1745.
21. Zacharski LR, Ornstein DL, Mamourian AC, (2000) Low-molecular-weight heparin and cancer. Semin Thromb Hemost 26 (Suppl 1): 69-77.
22. Casu B, Vlodavsky I, Sanderson RD, (2008) Non-anticoagulant heparins and inhibition of cancer. Pathophysiol Haemost Thromb 36: 195-203.
23. Raman R, Venkataraman G, Ernst S, Sasisekharan V, Sasisekharan R, (2003) Structural specificity of heparin binding in the fibroblast growth factor family of proteins. Proc Natl Acad Sci U S A 100: 2357-2362.
24. Smorenburg SM, Van Noorden CJ, (2001) The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev 53: 93-105.
25. Stone JP, Wagner DD, (1993) P-selectin mediates adhesion of platelets to neuroblastoma and small cell lung cancer. J Clin Invest 92: 804-813.
26. Heppner GH, Miller FR, Shekhar PM, (2000) Nontransgenic models of breast cancer. Breast Cancer Res 2: 331-334.
27. Nozawa H, Chiu C, Hanahan D, (2006) Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci U S A 103: 12493-12498.
28. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, et al. (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321: 1801-1806.
29. Leary RJ, Lin JC, Cummins J, Boca S, Wood LD, et al. (2008) Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc Natl Acad Sci U S A 105: 16224-16229.
30. Sasisekharan R, Shriver Z, Venkataraman G, Narayanasami U, (2002) Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer 2: 521-528.
31. Folkman J, (1985) Angiogenesis and its inhibitors. Important Adv Oncol pp. 42-62.
32. Kuderer NM, Ortel TL, Francis CW, (2009) Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J Clin Oncol 27: 4902-4911.
33. Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, et al. (2004) Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 22: 1944-1948.
34. Khasraw M, Pavlakis N, McCowatt S, Underhill C, Begbie S, et al. (2010) Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. Ann Oncol 21: 1302-1307.
35. Griffiths GO, Burns S, Noble SI, Macbeth FR, Cohen D, et al. (2009) FRAGMATIC: a randomised phase III clinical trial investigating the effect of fragmin added to standard therapy in patients with lung cancer. BMC Cancer 9: 355.
36. Shafat I, Ben-Arush MW, Issakov J, Meller I, Naroditsky I, et al. (2010) Preclinical and clinical significance of heparanase in Ewing's sarcoma. J Cell Mol Med.
37. Sideras K, Schaefer PL, Okuno SH, Sloan JA, Kutteh L, et al. (2006) Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc 81: 758-767.
38. Casu B, Guerrini M, Guglieri S, Naggi A, Perez M, et al. (2004) Undersulfated and glycol-split heparins endowed with antiangiogenic activity. J Med Chem 47: 838-848.
39. Ritchie JP, Ramani VC, Ren Y, Naggi A, Torri G, et al. (2011) SST0001, a Chemically Modified Heparin, Inhibits Myeloma Growth and Angiogenesis via Disruption of the Heparanase/Syndecan-1 Axis. Clinical cancer research: an official journal of the American Association for Cancer Research 17: 1382-1393.
40. Dredge K, Hammond E, Handley P, Gonda TJ, Smith MT, et al. (2011) PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models. British journal of cancer 104: 635-642.
41. Roy S, Lai H, Zouaoui R, Duffner J, Zhou H, et al. (2011) Bioactivity Screening of Partially Desulfated Low Molecular Weight Heparins: A Structure-Activity Relationship Study. Glycobiology (In press).
42. Folkman J, (1985) Regulation of angiogenesis: a new function of heparin. Biochem Pharmacol 34: 905-909.
43. Varki NM, Varki A, (2002) Heparin inhibition of selectin-mediated interactions during the hematogenous phase of carcinoma metastasis: rationale for clinical studies in humans. Semin Thromb Hemost 28: 53-66.
44. Vlodavsky I, Abboud-Jarrous G, Elkin M, Naggi A, Casu B, et al. (2006) The impact of heparanese and heparin on cancer metastasis and angiogenesis. Pathophysiol Haemost Thromb 35: 116-127.
45. Omuro AM, (2008) Exploring multi-targeting strategies for the treatment of gliomas. Curr Opin Investig Drugs 9: 1287-1295.
46. Ludwig RJ, Boehme B, Podda M, Henschler R, Jager E, et al. (2004) Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis. Cancer Res 64: 2743-2750.